Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention ; volume:7 ; number:1 ; day:25 ; month:10 ; year:2023 ; pages:1-12 ; date:12.2023
npj precision oncology ; 7, Heft 1 (25.10.2023), 1-12, 12.2023
- Urheber
-
Lee, Sang Beom
Pan, Jing
Xiong, Donghai
Palen, Katie
Johnson, Bryon
Lubet, Ronald A.
Shoemaker, Robert H.
Green, Jeffrey E.
Fernando, Romaine Ingrid
Sei, Shizuko
You, Ming
Wang, Yian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-023-00461-1
- URN
-
urn:nbn:de:101:1-2024020112340880312694
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Sang Beom
- Pan, Jing
- Xiong, Donghai
- Palen, Katie
- Johnson, Bryon
- Lubet, Ronald A.
- Shoemaker, Robert H.
- Green, Jeffrey E.
- Fernando, Romaine Ingrid
- Sei, Shizuko
- You, Ming
- Wang, Yian
- SpringerLink (Online service)
Ähnliche Objekte (12)
New Vaccine Therapy for Triple-Negative Breast Cancer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
New Vaccine Therapy for Triple-Negative Breast Cancer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
New Vaccine Therapy for Triple-Negative Breast Cancer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
Targeting a cell state common to triple‐negative breast cancers
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Characterizing triple-negative breast cancer tumors